The Uromigos

The Uromigos
  • 4,8 (5)
  • Medizin
  • Zweiwöchentlich

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

  1. 15. Juni

    Episode 510: ADCs in Prostate Cancer

    Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

    30 Min.

  2. 8. Juni

    Episode 509: ASCO 2026 Review

    This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.

    55 Min.

  3. 31. Mai

    Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer

    Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

    40 Min.

  4. 30. Mai

    Episode 507: ASCO 2026 - TALAPRO-3

    Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.

    42 Min.

  5. 30. Mai

    Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

    This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current tools, the importance of long-term follow-up, and future directions for integrating patient-centered metrics.

    20 Min.

  6. 30. Mai

    Episode 505 : ASCO 2026 - RAMPART

    James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.

    30 Min.

  7. 29. Mai

    Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer

    This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.

    41 Min.

  8. 25. Mai

    Episode 499: APCCC 2026 - Radioligands in Prostate Cancer

    This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.

    37 Min.
Alle anzeigen (477)

Bewertungen und Rezensionen

4,8
von 5
5 Bewertungen

Info

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Informationen

  • Erstellt von
    The Uromigos
  • Jahre aktiv
    2020 - 2026
  • Folgen
    477
  • Bewertung
    Unbedenklich
  • Copyright
    © The Uromigos
  • Sendungswebsite
    The Uromigos

Das gefällt dir vielleicht auch